Free Cash Flow to The Firm (FCFF)
Based on: 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27), 10-K (reporting date: 2017-04-28), 10-K (reporting date: 2016-04-29).
Item | Description | The company |
---|---|---|
FCFF | Free cash flow to the firm is the cash flow available to the Medtronic PLC suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. | Medtronic PLC FCFF decreased from 2019 to 2020 and from 2020 to 2021. |
Interest Paid, Net of Tax
Based on: 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27), 10-K (reporting date: 2017-04-28), 10-K (reporting date: 2016-04-29).
2 2021 Calculation
Cash paid for interest, tax = Cash paid for interest × EITR
= 582 × 6.80% = 40
Enterprise Value to FCFF Ratio, Current
Selected Financial Data (US$ in millions) | |
Enterprise value (EV) | 153,294 |
Free cash flow to the firm (FCFF) | 5,427 |
Valuation Ratio | |
EV/FCFF | 28.24 |
Benchmarks | |
EV/FCFF, Competitors1 | |
Abbott Laboratories | 22.63 |
Anthem Inc. | 13.77 |
Bristol-Myers Squibb Co. | 11.48 |
CVS Health Corp. | 9.56 |
Danaher Corp. | 27.63 |
HCA Healthcare Inc. | 14.64 |
Intuitive Surgical Inc. | 42.91 |
Stryker Corp. | 32.19 |
UnitedHealth Group Inc. | 22.48 |
EV/FCFF, Sector | |
Health Care Equipment & Services | 18.39 |
EV/FCFF, Industry | |
Health Care | 17.28 |
Based on: 10-K (reporting date: 2021-04-30).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | Apr 28, 2017 | Apr 29, 2016 | ||
---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||
Enterprise value (EV)1 | 183,640 | 139,945 | 148,881 | 131,974 | 140,523 | 135,959 | |
Free cash flow to the firm (FCFF)2 | 5,427 | 6,529 | 6,746 | 4,734 | 6,617 | 5,205 | |
Valuation Ratio | |||||||
EV/FCFF3 | 33.84 | 21.43 | 22.07 | 27.88 | 21.24 | 26.12 | |
Benchmarks | |||||||
EV/FCFF, Competitors4 | |||||||
Abbott Laboratories | 23.47 | 36.94 | 33.05 | 26.46 | 23.86 | — | |
Anthem Inc. | 12.74 | 6.04 | 12.73 | 24.58 | 13.91 | — | |
Bristol-Myers Squibb Co. | 10.52 | 11.63 | 23.39 | 15.74 | 24.15 | — | |
CVS Health Corp. | 10.30 | 9.42 | 12.30 | 17.89 | 14.20 | — | |
Danaher Corp. | 28.25 | 30.66 | 37.11 | 25.21 | 25.94 | — | |
HCA Healthcare Inc. | 16.71 | 11.93 | 17.25 | 18.06 | 19.24 | — | |
Intuitive Surgical Inc. | 56.47 | 76.70 | 54.58 | 57.79 | 47.07 | — | |
Stryker Corp. | 34.57 | 33.98 | 49.82 | 32.91 | 50.00 | — | |
UnitedHealth Group Inc. | 22.21 | 15.82 | 17.51 | 18.63 | 18.98 | — | |
EV/FCFF, Sector | |||||||
Health Care Equipment & Services | 19.12 | 16.83 | 20.86 | 21.73 | 21.15 | — | |
EV/FCFF, Industry | |||||||
Health Care | 16.84 | 18.95 | 19.68 | 19.02 | 19.19 | — |
Based on: 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27), 10-K (reporting date: 2017-04-28), 10-K (reporting date: 2016-04-29).
3 2021 Calculation
EV/FCFF = EV ÷ FCFF
= 183,640 ÷ 5,427 = 33.84
4 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
EV/FCFF | Enterprise value to free cash flow to the firm is whole company valuation indicator. | Medtronic PLC EV/FCFF ratio decreased from 2019 to 2020 but then increased from 2020 to 2021 exceeding 2019 level. |